OncoMed Pharmaceuticals, Inc. announced that Jakob Dupont, M.D., has resigned as the company’s Senior Vice President and Chief Medical Officer, due to personal and family-related issues. Dr. Dupont expects to return to Genentech/Roche in a position of significant responsibility in oncology clinical development. Dr. Dupont’s resignation will be effective on or about January 1, 2017 in order to facilitate a smooth transition. Robert Stagg, Pharm.D., will lead clinical development and clinical operations at the company. He has served as OncoMed’s Vice President, Clinical Research for over nine years. Jill Henrich, OncoMed’s Vice President, Regulatory Affairs for almost eight years, will continue to lead the company’s regulatory and quality functions. Both will report directly to OncoMed’s Chairman and CEO, Paul J. Hastings. OncoMed has initiated a process to identify candidates to fill the position of Chief Medical Officer.